JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258785

Human ASAP1 (DDEF1) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ASAP1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.

View Alternative Names

130 kDa phosphatidylinositol 4, 130 kDa phosphatidylinositol 4 5 biphosphate dependent ARF1 GTPase activating protein, 5-biphosphate-dependent ARF1 GTPase-activating protein, ADP-ribosylation factor-directed GTPase-activating protein 1, AMAP 1, ANK repeat and PH domain-containing protein 1, ARF GTPase-activating protein 1, ASAP1_HUMAN, Arf-GAP with SH3 domain, CentB4, Centaurin beta 4, DDEF 1, DDEF1 protein, Development and differentiation-enhancing factor 1, Differentiation-enhancing factor 1, KIAA1249, PAG 2, PIP2-dependent ARF1 GAP, ZG 14P

2 Images
Sanger Sequencing - Human ASAP1 (DDEF1) knockout HeLa cell lysate (AB258785)
  • Sanger seq

Unknown

Sanger Sequencing - Human ASAP1 (DDEF1) knockout HeLa cell lysate (AB258785)

Allele-2 : 1 bp insertion in exon2

Sanger Sequencing - Human ASAP1 (DDEF1) knockout HeLa cell lysate (AB258785)
  • Sanger seq

Unknown

Sanger Sequencing - Human ASAP1 (DDEF1) knockout HeLa cell lysate (AB258785)

Allele-1 : 1 bp deletion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258785-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ASAP1 knockout HeLa cell lysate", "number":"AB258785-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258785-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
ASAP1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ASAP1 also known as DDEF1 stands for ADP-Ribosylation Factor GTPase-Activating Protein 1 and has a molecular weight of approximately 130 kDa. It plays a mechanical role in actin cytoskeleton remodeling by regulating ARF (ADP-ribosylation factor) GTPases. These are involved in intracellular vesicular transport. ASAP1 localizes to the cytoplasm and shows high expression in invasive cancer cell lines with noticeable expression noted in tissues such as the brain liver and lung.
Biological function summary

ASAP1 interacts with components of the focal adhesion complex a group of proteins critical in signaling pathways that connect the extracellular matrix and the actin cytoskeleton. It modulates cell adhesion migration and invasion. ASAP1 binds to proteins like paxillin which further influences the dynamics of actin and membrane trafficking important for cellular rearrangements.

Pathways

ASAP1 plays roles in actin cytoskeleton reorganization pathways and integrin-mediated signaling pathways. These pathways are essential for cell motility and shape. In these contexts ASAP1 interacts with cortactin an actin-binding protein involved in the regulation of cytoskeletal dynamics necessary for the migration and invasion of cancer cells.

ASAP1 has associations with cancer progression particularly in breast and colorectal cancer. Research indicates that elevated ASAP1 expression correlates with aggressive tumor behavior and poor prognosis. Its interaction with paxillin during disease conditions highlights its involvement in tumor invasiveness and metastasis highlighting its potential as a therapeutic target in oncology.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com